Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 407899

Next Previous
Search
Drug Profile

SAR 407899

Alternative Names: SAR407899; SAR407899A

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Analgesics; Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies; Diabetic neuropathies; Erectile dysfunction; Hypertension; Kidney disorders; Pulmonary hypertension; Syndrome X

Most Recent Events

  • 31 Dec 2018 Discontinued - Phase-I for Syndrome X in Europe (PO) before December 2018 (Sanofi pipeline, February 2019)
  • 31 Dec 2018 Discontinued - Phase-II for Syndrome X in Denmark, USA, Netherlands, Netherlands, Sweden, South Korea (PO) before December 2018 (Sanofi pipeline, February 2019)
  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Syndrome X (microvascular angina) in 2022

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top